Experience with intravenous ferric carboxymaltose in patients with iron deficiency anemia
This review discusses the clinical experience with intravenous ferric carboxymaltose (FCM) for treating iron deficiency anemia (IDA) in adults intolerant to or unresponsive to oral iron, or with nondialysis-dependent chronic kidney disease. FCM allows administration of up to 750 mg per dose (totaling 1500 mg over two doses), delivered over
June 26, 2025
No Comments